2023-03-30 07:51:38 ET
- Reviva Pharmaceuticals press release ( NASDAQ: RVPH ): FY GAAP EPS of -$1.25 misses by $0.16 .
-
As of December 31, 2022, the Company’s cash and cash equivalents totaled approximately $18.5 million compared to approximately $29.7 million as of December 31, 2021.
Reviva believes that based on the current operating plan and financial resources, the Company’s cash as of December 31, 2022 will be sufficient to fund our current operating plans through the third quarter of 2023.
For further details see:
Reviva Pharmaceuticals GAAP EPS of -$1.25 misses by $0.16